Stories
Slash Boxes
Comments

SoylentNews is people

posted by martyb on Sunday February 10 2019, @01:53PM   Printer-friendly
from the just-greed dept.

Submitted via IRC for SoyCow1984

Drug companies are sitting on generics—43% of recently approved aren't for sale

Of the more than 1,600 generic drugs approved by the Food and Drug Administration since January of 2017, more than 700—or 43 percent—are not for sale in the US, according to a new analysis by Kaiser Health News.

The finding means that many pricy, brand-name drugs are not facing the competition that could help drive down soaring prices. Among the drugs missing in action are generic versions of the expensive blood thinner Brilinta and the HIV medication Truvada. Moreover, of the approved drugs that would offer a brand-name drug its first competition, 36 percent are being held off the market, the analysis found.


Original Submission

 
This discussion has been archived. No new comments can be posted.
Display Options Threshold/Breakthrough Mark All as Read Mark All as Unread
The Fine Print: The following comments are owned by whoever posted them. We are not responsible for them in any way.
  • (Score: 5, Insightful) by Thexalon on Sunday February 10 2019, @02:07PM (2 children)

    by Thexalon (636) on Sunday February 10 2019, @02:07PM (#799105)

    The basic idea of pay-to-delay is: I make a drug that rakes in $X a quarter right now. I'll pay you $Y to allow me to continue to gouge the customers. You like this deal because it means you get $Y without having to go through all the trouble of making and selling products, while I like this deal because it allows me to continue sell this drug at whatever price I feel like. And of course "whatever price I feel like" is now at least $X+$Y, and the only losers are the government, insurance companies, and the patients who actually need my drug to survive.

    That kind of stuff prevents the benefits of markets from ever taking hold.

    --
    "Think of how stupid the average person is. Then realize half of 'em are stupider than that." - George Carlin
    Starting Score:    1  point
    Moderation   +4  
       Insightful=3, Interesting=1, Total=4
    Extra 'Insightful' Modifier   0  
    Karma-Bonus Modifier   +1  

    Total Score:   5  
  • (Score: 3, Informative) by RandomFactor on Sunday February 10 2019, @02:25PM (1 child)

    by RandomFactor (3682) Subscriber Badge on Sunday February 10 2019, @02:25PM (#799110) Journal

    Pay for Delay
    Pay-for-Delay: When Drug Companies Agree Not to Compete [ftc.gov]

    One of the FTC’s top priorities in recent years has been to oppose a costly legal tactic that more and more branded drug manufacturers have been using to stifle competition from lower-cost generic medicines. These drug makers have been able to sidestep competition by offering patent settlements that pay generic companies not to bring lower-cost alternatives to market. These “pay-for-delay” patent settlements effectively block all other generic drug competition for a growing number of branded drugs. According to an FTC study, these anticompetitive deals cost consumers and taxpayers $3.5 billion in higher drug costs every year. Since 2001, the FTC has filed a number of lawsuits to stop these deals, and it supports legislation to end such “pay-for-delay” settlements.

    So apparently this is based on patent settlements. Still, they sound textbook anti-trust to me.

    Why is it the FTC that addresses this instead of the FDA?

    --
    В «Правде» нет известий, в «Известиях» нет правды
    • (Score: 2) by Thexalon on Sunday February 10 2019, @07:54PM

      by Thexalon (636) on Sunday February 10 2019, @07:54PM (#799190)

      It's the FTC rather than the FDA because the issue has to do with anti-trust and restraint of trade rather than the safety of the pills in question.

      --
      "Think of how stupid the average person is. Then realize half of 'em are stupider than that." - George Carlin